AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16480407 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Btx‐A) 133U
Number of subjects: 18
Study 16480407 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Btx‐A) 200U
Number of subjects: 18
Study 16480407 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 16480407 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Btx‐A) 133U and 200U
Number of subjects: 18
Study 14512806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bran bread (295 g daily)
Number of subjects: 10
Study 14512806 — intervention group
Group type: COMPARATOR
Intervention: Wheat bread (275 g daily, control)
Number of subjects: 10
Study 10599663 — intervention group
Group type: EXPERIMENTAL
Intervention: 350-mm2 Baerveldt implant
Number of subjects: 107
Study 10599663 — intervention group
Group type: COMPARATOR
Intervention: 500-mm2 Baerveldt implant
Number of subjects: 107
Study 8952239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral lidocaine patches
Number of subjects: 0
Study 8952239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1651893 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 300 mg/day orally for 7 days
Number of subjects: 6
Study 1651893 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 10 mg/kg, i.v.
Number of subjects: 6
Study 1651893 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 10 mg/kg/hr, i.v.
Number of subjects: 6
Study 1651893 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (10, 30, 100, 300 mg/kg, i.p.)
Number of subjects: 6
Study 10391798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (25 patients)
Number of subjects: 193
Study 10391798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicitropeptide (24 patients)
Number of subjects: 193
Study 10391798 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (20 patients)
Number of subjects: 193
Study 10391798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (29 patients)
Number of subjects: 193
Study 10391798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (22 patients)
Number of subjects: 193
Study 10391798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (26 patients)
Number of subjects: 193
Study 10391798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (19 patients)
Number of subjects: 193
Study 10391798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (28 patients)
Number of subjects: 193
Study 31240436 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary microRNA biomarker panel (miR‐6807‐5p, miR‐6856‐5p) combined with H. pylori status
Number of subjects: 306
Study 31240436 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary microRNA biomarker panel (miR‐6807‐5p, miR‐6856‐5p)
Number of subjects: 306
Study 27929721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Sodium Hyaluronate
Number of subjects: 176
Study 27929721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% Sodium Hyaluronate
Number of subjects: 176
Study 27929721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Sodium Hyaluronate
Number of subjects: 176
Study 27929721 — intervention group
Group type: COMPARATOR
Intervention: 0.05% Cyclosporine
Number of subjects: 176
Study 26087303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) plus usual care (UC)
Number of subjects: 15
Study 26087303 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 15
Study 24091274 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 21
Study 21527577 — intervention group
Group type: EXPERIMENTAL
Intervention: High red meat diet (420 g/d)
Number of subjects: 17
Study 21527577 — intervention group
Group type: COMPARATOR
Intervention: Low red meat diet (60 g/d)
Number of subjects: 17
Study 21527577 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet (0 g/d)
Number of subjects: 17
Study 21527577 — intervention group
Group type: COMPARATOR
Intervention: Medium red meat diet (120 g/d)
Number of subjects: 17
Study 18298484 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 12
Study 18298484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 12
Study 18298484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 12
Study 18298484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16645173 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (quit group)
Number of subjects: 32
Study 16645173 — intervention group
Group type: COMPARATOR
Intervention: Smoking (smoking control group)
Number of subjects: 32
Study 14652358 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Sodium (LS) diet (50 mmol Na+/d, >80 mmol K+/d)
Number of subjects: 108
Study 14652358 — intervention group
Group type: COMPARATOR
Intervention: Sodium supplementation (NaSp) treatment (120 mmol Na+/d)
Number of subjects: 108
Study 10992843 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane (2.3%)
Number of subjects: 81
Study 10992843 — intervention group
Group type: EXPERIMENTAL
Intervention: desflurane (12%)
Number of subjects: 81
Study 10992843 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane (4%)
Number of subjects: 81
Study 8763601 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal hyperthermia
Number of subjects: 341
Study 8763601 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral hyperthermia (TUT)
Number of subjects: 341
Study 8763601 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave hyperthermia (TUMH)
Number of subjects: 341
Study 1512151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia once a week (54.7% complete response rate)
Number of subjects: 240
Study 1512151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia twice a week (57.8% complete response rate)
Number of subjects: 240
Study 1512151 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (56.3% complete response rate)
Number of subjects: 240
Study 1512151 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe complications
Number of subjects: 240
Study 6609524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 731
Study 6609524 — intervention group
Group type: COMPARATOR
Intervention: Vibratory stimulation, high frequency TENS, low frequency TENS, placebo vibratory stimulation
Number of subjects: 731
Study 31651302 — intervention group
Group type: EXPERIMENTAL
Intervention: NIATx strategy (active implementation strategy)
Number of subjects: 49
Study 31651302 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control)
Number of subjects: 49
Study 29716897 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 26
Study 29716897 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1700 mg/day)
Number of subjects: 26
Study 29716897 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo with no lifestyle intervention)
Number of subjects: 26
Study 26377411 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery (20 eyes)
Number of subjects: 53
Study 26377411 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (33 eyes)
Number of subjects: 53
Study 24148093 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive process training (15 sessions, 45 min/session over 5 weeks)
Number of subjects: 59
Study 24148093 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive process training
Number of subjects: 59
Study 24148093 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 59
Study 22119204 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT+DE (androgen deprivation therapy + docetaxel-estramustine)
Number of subjects: 413
Study 22119204 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 413
Study 22119204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (docetaxel-estramustine)
Number of subjects: 413
Study 20189770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention measures to prevent noncompliance, including limited duration of the study, clear recommendations, power calculation, intensity of the intervention, involvement of the control group, waiting-list control group, and single-consent design nested within an observational study.
Number of subjects: 0
Study 20189770 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental variable method applied to estimate the intervention effect among compliers.
Number of subjects: 0
Study 20189770 — intervention group
Group type: COMPARATOR
Intervention: Noncompliance occurrence in lifestyle trials.
Number of subjects: 0
Study 17969201 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab induction, tacrolimus, and MMF (Arm 3)
Number of subjects: 312
Study 17969201 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and corticosteroids (Arm 1)
Number of subjects: 312
Study 17969201 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus, corticosteroids, and MMF (Arm 2)
Number of subjects: 312
Study 15755856 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate supplementation (1000 mg Ca/d)
Number of subjects: 143
Study 12149511 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva IgM and IgA antibodies to E. coli O157 lipopolysaccharide (LPS)
Number of subjects: 22
Study 10694073 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for urinary incontinence
Number of subjects: 0
Study 7784112 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiograph
Number of subjects: 60
Study 2327922 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-gloved operating team
Number of subjects: 841
Study 2327922 — intervention group
Group type: COMPARATOR
Intervention: Single-gloved operating team
Number of subjects: 841
Study 386962 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 22
Study 386962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31612335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahematomal catheter reaching the ventricles
Number of subjects: 74
Study 31612335 — intervention group
Group type: COMPARATOR
Intervention: Catheter placed exclusively in the ICH
Number of subjects: 74
Study 30585148 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-branded corn-based processed snacks
Number of subjects: 92
Study 30585148 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-source foods
Number of subjects: 92
Study 30585148 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread and vetkoek, snacks, and confectionery products
Number of subjects: 92
Study 30585148 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy foods (fruits and animal-source foods)
Number of subjects: 92
Study 30585148 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn-based processed snacks, sweets, lollipops, and biscuits
Number of subjects: 92
Study 30585148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient profiling score
Number of subjects: 92
Study 28306757 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (n=67)
Number of subjects: 136
Study 28306757 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (n=69)
Number of subjects: 136
Study 28306757 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise training vs Usual activity
Number of subjects: 136
Study 26275735 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (3 cycles of neoadjuvant chemotherapy: 100 mg/m² cisplatin and 85 mg/m² docetaxel followed by radiotherapy with 44 Gy in 22 fractions over 3 weeks)
Number of subjects: 232
Study 26275735 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 232
Study 23242470 — intervention group
Group type: EXPERIMENTAL
Intervention: pimecrolimus cream 1%
Number of subjects: 36
Study 23242470 — intervention group
Group type: EXPERIMENTAL
Intervention: mometasone furoate (1 mg/g)
Number of subjects: 36
Study 23242470 — intervention group
Group type: EXPERIMENTAL
Intervention: clobetasol propionate 0.05%
Number of subjects: 36
Study 23242470 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 36
Study 21319944 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg and esomeprazole magnesium 20 mg fixed-dose combination (FDC) twice daily for 12 months
Number of subjects: 239
Study 19190462 — intervention group
Group type: EXPERIMENTAL
Intervention: Leksell Gamma Knife PerfeXion
Number of subjects: 200
Study 19190462 — intervention group
Group type: COMPARATOR
Intervention: Leksell Gamma Knife 4C
Number of subjects: 200
Study 17126628 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric beverage (increased portion size from 360 g/12 fl oz to 540 g/18 fl oz)
Number of subjects: 33
Study 17126628 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric beverage (increased portion size)
Number of subjects: 33
Study 17126628 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric beverages
Number of subjects: 33
Study 14962399 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually Cued Color‐Shape task
Number of subjects: 3
Study 14962399 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditorily Cued Number‐Numeral task
Number of subjects: 3
Study 14962399 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious recollection component of the PDP task
Number of subjects: 3
Study 14962399 — intervention group
Group type: EXPERIMENTAL
Intervention: PDP estimates of conscious memory
Number of subjects: 3
Study 11730261 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH)
Number of subjects: 23
Study 11730261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9431836 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial format presentation
Number of subjects: 50
Study 9431836 — intervention group
Group type: COMPARATOR
Intervention: Patient data format presentation
Number of subjects: 50
Study 8472523 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamic acid (200 mg b.i.d.)
Number of subjects: 30
Study 8472523 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg b.i.d.)
Number of subjects: 30
Study 3718377 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg scopolamine
Number of subjects: 0
Study 3718377 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 0
Study 3718377 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine with 5 mg d-amphetamine
Number of subjects: 0
Study 3718377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3718377 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine and scopolamine with d-amphetamine (after discontinuation on day 5)
Number of subjects: 0
Study 29756213 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 60
Study 29756213 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic Collagen Matrix (XCM)
Number of subjects: 60
Study 29756213 — intervention group
Group type: COMPARATOR
Intervention: No Graft (NG)
Number of subjects: 60
Study 27261817 — intervention group
Group type: EXPERIMENTAL
Intervention: ZP‐025 (Monurelle Biogel®) vaginal gel, 1 or 2 times/daily intra‐vaginally for about 23 intermenstrual days
Number of subjects: 95
Study 27261817 — intervention group
Group type: EXPERIMENTAL
Intervention: ZP‐025 (Monurelle Biogel®) vaginal gel
Number of subjects: 95
Study 27261817 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment, lubricants on demand allowed)
Number of subjects: 95
Study 24944128 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training (FT); 3 × 40 min of small-sided football training per week for 10 weeks
Number of subjects: 97
Study 24944128 — intervention group
Group type: COMPARATOR
Intervention: Control (CON); maintained usual activities
Number of subjects: 97
Study 22755467 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit practice
Number of subjects: 60
Study 22755467 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit practice
Number of subjects: 60
Study 22755467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential practice (implicit first and then explicit)
Number of subjects: 60
Study 22755467 — intervention group
Group type: COMPARATOR
Intervention: Control group (measurements only)
Number of subjects: 60
Study 21084037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment (FK506)
Number of subjects: 0
Study 21084037 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate ointment (MPA)
Number of subjects: 0
Study 21084037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (MPA + FK506)
Number of subjects: 0
Study 21084037 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 18295469 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.125% with fentanyl 1 microg/mL at 8 mL/h
Number of subjects: 102
Study 18295469 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 1 microg/mL at 8 mL/h
Number of subjects: 102
Study 18295469 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% with fentanyl 1 microg/mL at 8 mL/h
Number of subjects: 102
Study 18295469 — intervention group
Group type: EXPERIMENTAL
Intervention: All three regimens
Number of subjects: 102
Study 15914548 — intervention group
Group type: EXPERIMENTAL
Intervention: FE(NO) measurements
Number of subjects: 97
Study 15914548 — intervention group
Group type: COMPARATOR
Intervention: Conventional guidelines (control group)
Number of subjects: 97
Study 11936565 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release formulation (500 mg IR)
Number of subjects: 12
Study 11936565 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release formulation (500 mg MR)
Number of subjects: 12
Study 11936565 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release formulation (750 mg MR)
Number of subjects: 12
Study 10892480 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat (3% sodium hyaluronate and 4% chondroitin sulfate)
Number of subjects: 82
Study 10892480 — intervention group
Group type: COMPARATOR
Intervention: Provisc (1% sodium hyaluronate)
Number of subjects: 82
Study 8821268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon defect left open (Group A)
Number of subjects: 61
Study 8821268 — intervention group
Group type: COMPARATOR
Intervention: Tendon defect closed (Group B)
Number of subjects: 61
Study 2140331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily
Number of subjects: 103
Study 2140331 — intervention group
Group type: COMPARATOR
Intervention: Josamycin 500 mg three times daily
Number of subjects: 103
Study 6815790 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone
Number of subjects: 30
Study 6815790 — intervention group
Group type: COMPARATOR
Intervention: Low dose methylprednisolone (control)
Number of subjects: 30
Study 6238861 — intervention group
Group type: EXPERIMENTAL
Intervention: C 48.401‐Ba cream (0.05% halomethasone)
Number of subjects: 117
Study 6238861 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate cream
Number of subjects: 117
Study 6238861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment containing 0.05% halomethasone
Number of subjects: 117
Study 6238861 — intervention group
Group type: COMPARATOR
Intervention: Ointment containing 0.1% betamethasone valerate
Number of subjects: 117
Study 6238861 — intervention group
Group type: EXPERIMENTAL
Intervention: C 48.401‐Ba ointment (0.05% halomethasone)
Number of subjects: 117
Study 6238861 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate ointment
Number of subjects: 117
Study 31381428 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning outside the comfort boundary (CB) at time to collision (TTC) of 1.7 seconds
Number of subjects: 31
Study 31381428 — intervention group
Group type: COMPARATOR
Intervention: Warning inside the comfort boundary (CB) at TTC of 2.6 seconds
Number of subjects: 31
Study 30384555 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping in addition to tendon and nerve gliding exercises
Number of subjects: 21
Study 30384555 — intervention group
Group type: COMPARATOR
Intervention: Tendon and nerve gliding exercises
Number of subjects: 21
Study 27548106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile cortisol infusion
Number of subjects: 41
Study 27548106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (GR antagonist)
Number of subjects: 41
Study 27548106 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (MR antagonist)
Number of subjects: 41
Study 27548106 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH-arginine vasopressin stimulation
Number of subjects: 41
Study 27548106 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal vs addback of sex steroids
Number of subjects: 41
Study 27548106 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ACTH secretion between men and women
Number of subjects: 41
Study 25231095 — intervention group
Group type: EXPERIMENTAL
Intervention: CD133(+) cells
Number of subjects: 28
Study 25231095 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 28
Study 22492430 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 87
Study 22492430 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial RFA
Number of subjects: 87
Study 22492430 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures with 3D electroanatomic mapping
Number of subjects: 87
Study 22492430 — intervention group
Group type: EXPERIMENTAL
Intervention: Any ablation strategy
Number of subjects: 87
Study 19268928 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate (25 mg/day) and vitamin E (400 mg/day)
Number of subjects: 60
Study 19268928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19268928 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and vitamin E
Number of subjects: 60
Study 18624803 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 15 sessions over 3 months)
Number of subjects: 1613
Study 18624803 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care alone)
Number of subjects: 1613